0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV-135.96%PremiumDec 20, 2024Expiry Date2.88Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.74Leverage Ratio--Theta--Rho--Eff Leverage--Vega
MediciNova Stock Discussion
📊⚡️📊
MediciNova Inc - Patent Is Expected to Expire No Earlier Than May 26, 2042
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
MediciNova (NASDAQ: MNOV) announced it will receive monetary damages following the settlement of Sanofi-Novartis litigation. The company plans to use this non-dilutive fundingto support ongoing clinical development programs, particularly focusing on their late-stage pipeline targeting inflammatory, metabolic, and neurodegenerative diseases. The settlement validates MediciNova's in...
Medicinova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
No comment yet